A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer

Trial Details

NCT ID
NCT06555068
Phase
PHASE1 / PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • HRS-6209 in Combination with Fulvestrant
  • HRS-6209 in Combination with HRS-1358
  • HRS-6209 in Combination with Letrozole
  • HRS-6209 in Combination with HRS-8080
  • HRS-6209 in Combination with HRS-9813 and Letrozole
  • HRS-6209 in Combination with HRS-9813 and HRS-8080
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Females aged 18-75 years (inclusive);
  • ECOG performance status (PS) score of 0-1;
  • Patients with histopathologically confirmed metastatic or unresectable locally advanced breast cancer;
  • Patients with advanced malignant solid tumors confirmed by histopathology or cytopathology, who have failed standard treatment, or for whom no effe…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →